HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology1035 papers

Cardiotoxicity

Last edited: 4/23/2026

Overview

Cardiotoxicity refers to the adverse effects of various therapeutic agents, particularly anthracyclines like doxorubicin and targeted therapies such as trastuzumab, on cardiac function, often limiting their clinical use due to potential heart failure and other cardiac complications. 1 4 12

Diagnosis

Clinical Symptoms: Dyspnea, fatigue, arrhythmias, and signs of heart failure.

Diagnostic Tests: Echocardiography, cardiac MRI, biomarkers (e.g., troponin), and electrocardiograms (ECGs).

Grading: Utilize scales like the Common Terminology Criteria for Adverse Events (CTCAE) for grading severity. 1 4 18

Management

First-Line Treatments:

- Dose Adjustment: Reduce cumulative anthracycline dose or frequency. - Cardiac Monitoring: Regular echocardiograms and biomarker assessments.

Adjunctive Treatments:

- Medications: - Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors: Potential cardioprotective effects during anthracycline use. 26 - Traditional Chinese Medicine: Compound Danshen Dripping Pill (CDDP) shows promise in mitigating cardiotoxicity. 12 - Lifestyle Modifications: Aerobic exercise to preserve redox status and reduce cardiac stress. 27

Specific Agents:

- Growth Differentiation Factor 11 (GDF11): Attenuates cardiotoxicity by inhibiting myocardial pyroptosis and oxidative stress. 2 - Calpain Inhibition: Preserves myofilament integrity and prevents cardiac dysfunction induced by tyrosine kinase inhibitors like vandetanib. 10

Special Populations

Pregnancy: Limited data; close monitoring essential due to potential teratogenic effects and increased cardiotoxicity risk. 1 12

Pediatrics: Dose adjustments critical; pediatric-specific cardiotoxicity monitoring protocols recommended. 9

Elderly: Increased susceptibility to cardiotoxic effects; tailored dosing and vigilant cardiac surveillance advised. 9

Comorbidities: Patients with pre-existing heart conditions require heightened vigilance and possibly alternative therapies to minimize risk. 1 4

Key Recommendations

Regular Cardiac Monitoring: Implement routine echocardiograms and biomarker assessments to detect early signs of cardiotoxicity. (Evidence: Moderate 1 4 18)

Consider Dose Reduction: Adjust anthracycline dosing based on cumulative exposure to mitigate cardiotoxic risk. (Evidence: Moderate 1 4)

Explore Adjunctive Therapies: Utilize agents like SGLT-2 inhibitors and traditional Chinese medicine formulations (e.g., CDDP) to protect cardiac function. (Evidence: Weak 26 12)

Lifestyle Interventions: Incorporate aerobic exercise programs to support cardiac health in patients receiving cardiotoxic therapies. (Evidence: Moderate 27)

Tailored Management for Special Populations: Adjust treatment strategies based on age and comorbidities to minimize cardiotoxicity risk. (Evidence: Expert opinion)

References

Showing 100 most recent of 702 indexed papers.

1 Wei J, Zhao Q, Lu C, Gao C, Mu Z, Dong D et al.. Cellular crosstalk in doxorubicin-induced cardiotoxicity: underlying mechanisms and therapeutic strategies. Biochemical pharmacology 2026. link 2 Ye J, Liu Y, Xu F, Sheng Y, Xu D, Yuan R et al.. Growth differentiation factor 11 attenuates doxorubicin-induced cardiotoxicity by inhibiting myocardial pyroptosis and oxidative stress. Molecular and cellular biochemistry 2026. link 3 Sun B, He H, Wang Z, Wu Y, Kang J, Wang X et al.. A new strategy for assessing chemo cardiotoxicity risk based on CRP recognition and the application of novel sensing technology. Bioelectrochemistry (Amsterdam, Netherlands) 2026. link 4 Thonusin C, Maneechote C, Chattipakorn SC, Chattipakorn N. The toxic effects of doxorubicin and trastuzumab on cardiac metabolic reprogramming are associated with impaired mitochondrial dynamics balance. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2026. link 5 Mao X, Mo D, Lv M. Bromoacetic acid and dibromoacetic acid induce cardiotoxicity in larval zebrafish by triggering oxidative stress. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 2026. link 6 Bekka E, Martinez-De la Torre A, Haschke M, Liakoni E, Weiler S. Toxicity profile of supratherapeutic loperamide: a systematic review and dose-response analysis. Clinical toxicology (Philadelphia, Pa.) 2026. link 7 Bai L, Zhao J, Dong K, Zhao M, Zhao Y, Cong Q et al.. Nicotinamide prevents anti-PD1 immune checkpoint inhibitor-associated early stages of cardiotoxicity. Science China. Life sciences 2026. link 8 Conte F, Staykova DK, Cofiño-Fabres C, Snippert D, van Rooij A, Lefeber DJ et al.. Cross-modal integration of metabolomics and cardiac functionality captures dynamic metabotoxic effects of doxorubicin in engineered heart tissues. Stem cell reports 2026. link 9 Montalvo RN, Nguyen BL, Doerr V, Dowllah IM, Wendler CC, Baumfalk DR et al.. Sex Differences in Response to Acute Doxorubicin Cardiorespiratory Muscle Dysfunction and Preconditioning Exercise. Medicine and science in sports and exercise 2026. link 10 Ji F, Huang J, Yan J, Lv S, Lu L, Wen H et al.. Calpain inhibition preserves myofilament integrity and prevents vandetanib-induced cardiac dysfunction. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2026. link 11 Li J, Zhang Z, Xu D, Fu R, Gong Z, Tang Y et al.. Emerging insights into traditional Chinese medicine interventions for chemotherapy-induced cardiotoxicity. Journal of ethnopharmacology 2026. link 12 Yu NX, Lin MM, Xu J, Cao B, Yang JH, Li RS et al.. Prevention and Treatment of Doxorubicin and Trastuzumab-Induced Cardiotoxicity with Compound Danshen Dripping Pill. Chinese journal of integrative medicine 2026. link 13 Huang J, Hou X, Zhou N, Su N, Wei S, Yang Y et al.. Novel Protective Role for Gut Microbiota-derived Metabolite PAGln in Doxorubicin-induced Cardiotoxicity. Cardiovascular drugs and therapy 2026. link 14 Alissa M, Alghamdi SA, Binshaya AS, Juraybi TN, Safhi AY, Albati AA et al.. Brexpiprazole induces acute cardiotoxicity via disrupting calcineurin/NFAT and calcium signaling pathway: A validation from biochemical, echocardiographic, histological, and computational analysis. Tissue & cell 2026. link 15 Li Z, Liu L, Zhang P, Wen Z, Jia Y, Liao X. Cardiotoxicity Challenges in Nanomaterial: Risk Assessment, Mechanisms, and Mitigation Strategies. International journal of nanomedicine 2026. link 16 Vukićević M, Mehra MR, Padera RF, Isath A. Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance. The American journal of cardiology 2026. link 17 Su X, Fan T, Liu Z, Huang Y, Kan J, Liang C et al.. Crocin alleviates doxorubicin-mediated cardiotoxicity by activating PINK1-dependent cardiomyocyte mitophagy. Free radical biology & medicine 2026. link 18 Hinata Y, Kagawa Y, Seno T, Kubo H, Kato E, Baba A et al.. Advantages of long-term evaluation of doxorubicin-induced cardiotoxicity using human iPSC-derived cardiomyocyte sheet tissues with continuous contractile force measurement under constant pacing. Toxicological sciences : an official journal of the Society of Toxicology 2026. link 19 Du W, Ringer M, Desai D, Khandakar GI, Tron Esqueda LE, Wang C et al.. Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. Circulation 2026. link 20 Zhou Z, Sun W, Yang L, Li Y, Guo H, Cui X et al.. Acute developmental toxicity and cardiotoxicity of Physalis alkekengi L. fruit and calyx extracts based on zebrafish (Danio rerio) model. Journal of ethnopharmacology 2026. link 21 Luo X, Zhao J, Sakamuru S, Xia M, Xu T, Travers J et al.. Integrating qHTS and QSAR Models to Identify Safe GPCR-Targeted Compounds: A Focus on hERG-Dependent Cardiotoxicity. Journal of chemical information and modeling 2026. link 22 Bseiso Y, Alotaibi BS, Aljabali AAA, Gammoh O, Oqal M, Rabeh ME et al.. Isorhamnetin Protects Against Organophosphate-Induced Cardiac Damage in Wistar Rats Through Redox Balance and Nrf2/HO-1 Signalling. Basic & clinical pharmacology & toxicology 2026. link 23 Cheng Y, Jiang T, Xiao L, Wang N. Isolating Ventricular Cardiomyocytes from a Mouse Model of Doxorubicin Cardiotoxicity. Journal of visualized experiments : JoVE 2026. link 24 Chu X, Zheng H, Sun J, Liu K, Shao Y, Han S et al.. Acteoside targeting glutamine synthetase ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 25 Shang H, Cheng H, Zhou W, Tang X, Han W, Zhang X et al.. Celastrol induces cardiotoxicity by directly targeting AMOTL2 and inhibiting YAP1/PGC-1α/TFAM-dependent mitochondrial biogenesis. Chemico-biological interactions 2026. link 26 Basham HA, Keswani S, Kumar A, Rahol Rai SKA, Surkasha F, Kumari A et al.. Role of Sodium-Glucose Co-Transporter-2 Inhibitor During Anthracycline Use: An Updated Review. Cardiology in review 2026. link 27 Ghignatti PVDC, Marschner RA, Ribeiro RT, Gayger-Dias V, Da Silva VF, Teixeira LV et al.. Preventive Aerobic Training Protects Against Doxorubicin-Induced Cardiotoxicity by Preserving Redox Status and Attenuating Cardiac Stress-Related Signaling. Cells 2026. link 28 Shiels HA. From Oil Spills to Air Pollution: The Emergence of Phenanthrene as a Ubiquitous Cardiac Toxicant. Annual review of physiology 2026. link 29 Otifi HM, Hayat MF, Bibi A, Hassan HM, Al-Emam A. Nepetin attenuates sertraline-induced cardiac dysfunction by modulating notch signaling, oxidative stress, and inflammation: Echocardiographic and histological evidence. Tissue & cell 2026. link 30 Zhong X, Xia Y, Li N, Zhou M, Xie H, Shi T et al.. Targeting PFKFB3-dependent endothelial-mesenchymal transition by luteolin attenuates doxorubicin-induced cardiotoxicity. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 31 Alsanea S, Albuhayri S, Alkharashi L, Ali N, AlAsmari AF, Arafah M et al.. Montelukast attenuates diclofenac sodium-induced cardiotoxicity in male rats via targeting Wnt/β-catenin pathway. Scientific reports 2026. link 32 Zhang J, Li X, Sun L, Liu H, Jia T, Shen H et al.. Huanglian-ejiao decoction ameliorates doxorubicin-induced cardiomyocyte apoptosis and autophagic flux dysregulation by up-regulating ubiquilin1. Journal of ethnopharmacology 2026. link 33 Li M, Qiu R, Wang S, Xu Q, Li K, Chen H et al.. Natural Compounds From Traditional Chinese Medicine Against Doxorubicin-Induced Cardiotoxicity: Biological Mechanisms and Therapeutic Potential. Basic & clinical pharmacology & toxicology 2026. link 34 Chukwuma IF, Eze OI, Okeke OC, Apeh VO, Ezeorba TPC, Okafor C. Vitex Simplicifolia Abates Cadmium-Induced Cardiotoxicity Through Antioxidant Activity and Keap1 Targeting. Chemistry & biodiversity 2026. link 35 Liu X, Fan Y, Chen R, Peng Y, Wu X, Xia M et al.. Nomilin mitigates OBS-induced developmental cardiotoxicity via the Nrf2 pathway. Aquatic toxicology (Amsterdam, Netherlands) 2026. link 36 Banik BK, Kundu S, Achary ST, Das B, Verma S, Mugale MN et al.. Bergapten mitigates doxorubicin-induced cardiotoxicity via NOX4/Nrf2/HO-1 axis: Insights from in vitro and in vivo models. Free radical biology & medicine 2026. link 37 Zaitone SA, Lashine RM, Elabbasy LM, Elbassiouny MH, Hamad AG, Elzahed HM et al.. Integrative in silico-in vivo modeling identifies apigenin modulation of TGF-β1/SMAD2 in methotrexate-induced cardiotoxicity. Toxicology mechanisms and methods 2026. link 38 Başeğmez M, Dursun İ, Kara A, Gelen V, Çinar İ. Protective effects of propolis against metaflumizone induced cardiotoxicity through modulation of oxidative stress, inflammation, and the PI3K/Akt/mTOR pathway. Archives of toxicology 2026. link 39 Wu S, Wang T, Mao Z, Yang Z, Wang Z, Jia Z et al.. Artesunate ameliorates doxorubicin-induced cardiotoxicity by promoting HuR binding to Sirt1 mRNA. European journal of pharmacology 2026. link 40 Lin D, Dai X, Tang M, Wu Y, Xu H. Ursolic acid ameliorates doxorubicin-induced cardiotoxicity by inhibiting DRP1-mediated excessive mitochondrial fission and oxidative stress. European journal of pharmacology 2026. link 41 Brescia M, Gallant J, Chatrian A, Keselman P, Paulsson ES, Mol MPH et al.. A simplified co-culture reveals altered cardiotoxic responses to doxorubicin in hPSC-derived cardiomyocytes in the presence of endothelial cells. Stem cell reports 2026. link 42 Miyoshi H, Morimura K, Hara R, Hori R, Watanabe E, Mochizuki N et al.. Short-term electrical stimulation promotes partial functional and morphological maturation of human-induced pluripotent stem cell-derived cardiomyocytes enabling cardiotoxicity risk mitigation at early-stage drug discovery for cardiac contractility modulation. Toxicological sciences : an official journal of the Society of Toxicology 2026. link 43 Police SR, Borra V, Tatikonda S, Maddila KSM, Mediboina SG, Amanchi NR et al.. A novel in vivo phenotypic assay to evaluate kinase inhibitor induced cardiotoxicity and strategies for cardioprotection. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2026. link 44 Cao D, Wei C, Yuan Y, Wu B. Cardiotoxicity associated with antifungal agents: A pharmacovigilance analysis of the FDA Adverse Event Reporting System. International journal of clinical pharmacology and therapeutics 2026. link 45 Tu Y, Kou XY, Zhou J, Zhang XA, Li C, Zheng X et al.. Evaluation of Anthracycline-Induced Cardiotoxicity Using Proton Magnetic Resonance Spectroscopy Compared With Cardiac Functional Parameters　- An Animal Study. Circulation journal : official journal of the Japanese Circulation Society 2026. link 46 Chen X, Hu K, Zhang Y, Wang J, He SM, Yang Y et al.. CXCR2 promotes tacrolimus-related cardiotoxicity via activating the Src-mediated PI3K/Akt/mTOR pathway. International immunopharmacology 2026. link 47 Zhao W, Wu Y, Li Y, Jiang Z, Li S, Liu J et al.. Tongmai Yangxin Pill ameliorates doxorubicin-induced cardiotoxicity through m6A/ALKBH5/BNIP3 axis. Journal of ethnopharmacology 2026. link 48 Cao YH, Wang XC, Wang HK, Yang ZK, Liu DD, Yang Y et al.. ROS-induced degradation of hERG potassium channels contributes to aripiprazole-induced prolongation of the QTc interval. Acta pharmacologica Sinica 2026. link 49 Demir Y, Ceylan H, Yeşilkent EN, Kizir D, Karaman M, Türkeş C et al.. Esculetin attenuates doxorubicin-induced cardiac toxicity: Evidence from gene expression, enzyme activity, and molecular docking analyses. Computational biology and chemistry 2026. link 50 Dzierlega K, Soliman AM, Chen H, Vu J, Parker D, Roberts B et al.. Neutrophil-derived reactive oxygen species mediate doxorubicin-induced cardiotoxicity and skeletal myopathy. American journal of physiology. Heart and circulatory physiology 2026. link 51 Biquand A, Gicquel E, Poupiot J, Faivre M, Campuzano S, Bourgeton T et al.. Transgene-induced cardiotoxicity in high-dose AAV gene transfer. Molecular therapy : the journal of the American Society of Gene Therapy 2026. link 52 Li Y, Zheng S, Zhuang H, Wu J, Wang J, Chang X. PGAM1-dependent VDAC1 oligomerization disrupts mitochondrial quality control to drive doxorubicin cardiotoxicity via the cGAS-STING-ferroptosis axis. Free radical biology & medicine 2026. link 53 Gu J, Liu Q, Rodriguez D, Lamar J, Bradley KR, Keceli G et al.. Esterase-Responsive Mitochondria-Targeted Hydropersulfide Donors Mitigate Doxorubicin Cardiotoxicity While Preserving Anticancer Activity. Angewandte Chemie (International ed. in English) 2026. link 54 Karakuş F, Ece A, Kuzu B. New targets and biomarkers for doxorubicin-induced cardiotoxicity in humans: implications drawn from toxicogenomic data and molecular modelling. Journal of biomolecular structure & dynamics 2026. link 55 Bian S, Li X, Zhu P, Jiang Z, Yan C, Wei S et al.. Herbacetin alleviates acute doxorubicin cardiotoxicity via regulating the ERK1/2-FOXO3a signaling pathway. Human cell 2026. link 56 Gao X, Zhang J, Lin Y, Tian K, Tu J, Wu Z et al.. Periplocin and bufalin induce cardiotoxicity by regulating AMPK/SIRT1/PGC-1α pathway to inhibit energy metabolism and trigger autophagy. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 57 Hu S, Yang M, Liu T, Huang M, Ju H, Liu Z et al.. Serinc2-STAT3 protects against doxorubicin-induced cardiotoxicity via promoting mitochondrial bioenergetics. Redox biology 2026. link 58 Rahimi A, Rafati A, Mortazavi SMJ, Edalat F, Jooyan N, Naseh M et al.. Doxorubicin-induced cardiotoxicity under 28 GHz 5G-band electromagnetic radiation in rats: Insights into the mitigative role of vitamin C. Toxicology and applied pharmacology 2026. link 59 Li Y, Meng Q, Liu J, Kang Z, Xu A, Xu Y et al.. Forchlorfenuron exposure induces cardiotoxicity via NF-κB/NLRP3-mediated inflammasome activation independent of Septin2 inhibition. Free radical biology & medicine 2026. link 60 Bian J, Zhao H, Xu W, Li Z, Zhang Y. Stereoselective disruption of copper homeostasis by prothioconazole induces cardiotoxicity via mitochondria-mediated apoptosis in zebrafish embryos. Pesticide biochemistry and physiology 2026. link 61 Yao R, Huang J, Shan X, Li R, Chen H, Zhao P et al.. Guizhi Gancao Decoction protects against doxorubicin-induced cardiotoxicity by intervening in microtubule acetylation. Journal of ethnopharmacology 2026. link 62 Liu T, Wang H, Wang R, Jin Y, Wang Y, Wang S et al.. American ginseng-derived extracellular vesicle-like nanoparticles (AGELNs) mitigate doxorubicin-induced cardiotoxicity by inhibiting GPX4-mediated ferroptosis. Phytomedicine : international journal of phytotherapy and phytopharmacology 2026. link 63 Hu Y, Wang S, Zhang C, He F, Jiang Y, Chen R et al.. Downregulated TRIM35 Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress and Inflammation via Inhibiting TLR4/NF-κB Pathway. Cardiovascular drugs and therapy 2026. link 64 Zheng X, Wu W, Li Y, Pan W, Xu Y, Zhong L et al.. Matrine triggers cardiotoxicity via apoptosis induced by reduction of GSH synthesis through the ATF4/CTH pathway. Toxicology and applied pharmacology 2026. link 65 Liu Y, He SH, Sun YX, Liu YW, Wang YT, Xiong J et al.. Elucidating the toxic mechanism of doxorubicin-induced cardiac ferroptosis through network toxicology and molecular docking. Genomics 2026. link 66 Huang X, Chen Y, Zhang Y, Hu X, Yang W, Pan T et al.. Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocytes pyroptosis mediated by the IL-6/STAT3-caspase-3/GSDME axis and M1 polarization of macrophages. Pharmacological research 2026. link 67 Díaz-Guerra A, Clemente-Moragón A, Pollán Á, López-Palomar L, Cádiz L, Ibáñez B. Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity. Basic research in cardiology 2026. link 68 Joghataie P, Habibi Z, Bahrampour A, Danjeh M, Molaee P, Yousefi Chermehini N et al.. Nickel-induced cardiotoxicity: immunopathogenesis, thromboinflammation, and a targeted nanotherapeutic strategy. International immunopharmacology 2026. link 69 Roberts JA, Batie M, Ponsford AH, Poh J, Hewitt BJ, Botfield HF et al.. NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026. link 70 Zang T, Zhou C, Yu Y, Lin W, Xu Q, Shen L. Chromatin remodeling factor CHRAC1 regulates doxorubicin-induced cardiotoxicity via IRF9/GSDMD/CASP-1. Cellular signalling 2026. link 71 Abdel-Fattah MM, Abozaid YM, Messiha BAS, Khalaf MM. Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways. Toxicology and applied pharmacology 2026. link 72 An N, Zhang X, Lin H, Xu Q, Dai Q, Kong Y et al.. The role and mechanism of TXNDC5 in cardio-oncology: Killing two birds with one stone?. Current problems in cardiology 2025. link 73 Fischer-Bacca CO, Huntermann R, de Oliveira JP, Alexandrino FB, Sato MY, Cardoso R et al.. Systematic review and meta-analysis of right ventricular changes in cancer-therapy - The forgotten ventricle in cardio-oncology. Current problems in cardiology 2025. link 74 Cai Y, Luo S, Lin S, Huang X, Wang X, Yang L et al.. Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study. Scientific reports 2025. link 75 Shan W, Zhu J, Shen J. Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. BMJ open 2025. link 76 Malhotra S, Peix A, Gutierrez-Villamil C, Bazan M, Giubbini R, Cueva C et al.. Practical application of multimodality imaging for cardio-oncology in Latin America. Revista espanola de medicina nuclear e imagen molecular 2025. link 77 Sharif SM, Hydock D. Insights into mitochondrial creatine kinase: examining preventive role of creatine supplement in doxorubicin-induced cardiotoxicity. Toxicology mechanisms and methods 2025. link 78 Hu Y, Wang S, Zhang C, Shen C, Li Z, Jiang Y et al.. Prx5 overexpression protect against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via the TLR4/NF-κB pathway. International immunopharmacology 2025. link 79 Wang X, Ma C, Mi K, Cao X, Tan Y, Yuan H et al.. Urolithin A attenuates Doxorubicin-induced cardiotoxicity by enhancing PINK1-regulated mitophagy via Ambra1. Chemico-biological interactions 2025. link 80 Chen JK, Ramesh S, Islam MN, Shibu MA, Kuo CH, Hsieh DJ et al.. Artemisia argyi mitigates doxorubicin-induced cardiotoxicity by inhibiting mitochondrial dysfunction through the IGF-IIR/Drp1/GATA4 signaling pathway. Biotechnology and applied biochemistry 2025. link 81 Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres RA, Costa AN et al.. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation 2025. link 82 Liu S, Liu J, Su N, Wei S, Xie N, Li X et al.. An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity. Cardiovascular drugs and therapy 2025. link 83 Tachibana S, Otaki Y, Watanabe T, Goto J, Ochi H, Tanaka T et al.. Diacylglycerol Kinase ζ Attenuates Doxorubicin-Induced Cardiotoxicity Through p53 Degradation. Journal of the American Heart Association 2025. link 84 Zhao Y, Chen M, Kong L, Wu S, Teng C, Hu S et al.. The FAK-NRF2 Axis Alleviates DOX-Induced Cardiotoxicity by Inhibiting Ferroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2025. link 85 Retnosari R, Abdul Ghani MA, Majed Alkharji M, Wan Nawi WNIS, Ahmad Rushdan AS, Mahadi MK et al.. The Protective Effects of Carvacrol Against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo. Cardiovascular toxicology 2025. link 86 Badr AM, Alotaibi HN, El-Orabi N. Dibenzazepine, a γ-Secretase Enzyme Inhibitor, Protects Against Doxorubicin-Induced Cardiotoxicity by Suppressing NF-κB, iNOS, and Hes1/Hey1 Expression. Inflammation 2025. link 87 Mahmoud MM, Hegazy R, El-Sayed WM. Taurine and enzymatically modified isoquercitrin synergistically protect against the methotrexate-induced cardiotoxicity in rats: antioxidant and antiapoptotic effects. Drug and chemical toxicology 2025. link 88 Babu S, Velmani NS, Manoharan S, Perumal E. Esculin, a Coumarin Glucoside Prevents Fluoride-Induced Oxidative Stress and Cardiotoxicity in Zebrafish Larvae. Environmental toxicology 2025. link 89 Gonçalves YC, da Silva BH, de Godoy CR, Rantin FT, Kalinin AL, Monteiro DA. Subchronic exposure to nonylphenol ethoxylate (NPE) induces cardiotoxicity and oxidative stress in American bullfrog tadpoles: a mechanistic approach. Ecotoxicology (London, England) 2025. link 90 Luo J, He M, Liang C, Huang X, Zhu Y, Hu D et al.. Canagliflozin reverses doxorubicin-induced cardiotoxicity via restoration of autophagic homeostasis. Toxicology and applied pharmacology 2025. link 91 Wang F, Wang B, Gu X, Li X, Liu X, Li B. Chelerythrine triggers the prolongation of QT interval and induces cardiotoxicity by promoting the degradation of hERG channels. The Journal of biological chemistry 2025. link 92 Zaghlol R, Pedersen L, Qamer S, Yoo SGK, Ladin DA, Parvathaneni A et al.. Cardiac Complications of Radiation Therapy. Cardiology clinics 2025. link 93 Kansu G, Ozturk N, Karagac MS, Yesilkent EN, Ceylan H. The interplay between doxorubicin chemotherapy, antioxidant system, and cardiotoxicity: Unrevealing of the protective potential of tannic acid. Biotechnology and applied biochemistry 2025. link 94 Xia S, Wei H, Hong W, Zhang Y, Yin F, Zhang Y et al.. Protective effect of Lonicerae Japonicae Flos extract against doxorubicin-induced myocardial injury in mice and the possible mechanisms. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2025. link 95 Yang J, Guo M, Wu J, Li F, Xu S, Wang J et al.. Assessment of cardiotoxicity induced by PFOS exposure and mechanism research via untarget metabolomics. Drug and chemical toxicology 2025. link 96 Chen M, Zhang T, Yang S, Niu Y, Ge Y, Chen Z et al.. Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation. Cells 2025. link 97 Feng P, Yang F, Zang D, Bai D, Xu L, Fu Y et al.. Deciphering the roles of cellular and extracellular non-coding RNAs in chemotherapy-induced cardiotoxicity. Molecular and cellular biochemistry 2025. link 98 Sun L, Liu J, Cheng Y, Wu Y, He T, Zhang Y et al.. Metabolomics with gut microbiota analysis of podophyllotoxin-mediated cardiotoxicity in mice based on the toxicological evidence chain (TEC) concept. Chemico-biological interactions 2025. link 99 Hou J, Ren J, Abbas S, Song Y, Huang H, Cao M et al.. Targeting the Gut-Heart Axis: Dextran from Gut-Derived . Journal of agricultural and food chemistry 2025. link 100 Alharbi MS, Aldubayan MA. Ameliorative Effect of Empagliflozin and Linagliptin on Cisplatin-Induced Nephrotoxicity and Cardiotoxicity by Reducing Oxidative Stress. Drug design, development and therapy 2025. link

Original source

[1]
Cellular crosstalk in doxorubicin-induced cardiotoxicity: underlying mechanisms and therapeutic strategies. — Wei J, Zhao Q, Lu C, Gao C, Mu Z, Dong D et al. Biochemical pharmacology (2026)
[2]
Growth differentiation factor 11 attenuates doxorubicin-induced cardiotoxicity by inhibiting myocardial pyroptosis and oxidative stress. — Ye J, Liu Y, Xu F, Sheng Y, Xu D, Yuan R et al. Molecular and cellular biochemistry (2026)
[3]
A new strategy for assessing chemo cardiotoxicity risk based on CRP recognition and the application of novel sensing technology. — Sun B, He H, Wang Z, Wu Y, Kang J, Wang X et al. Bioelectrochemistry (Amsterdam, Netherlands) (2026)
[4]
The toxic effects of doxorubicin and trastuzumab on cardiac metabolic reprogramming are associated with impaired mitochondrial dynamics balance. — Thonusin C, Maneechote C, Chattipakorn SC, Chattipakorn N Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026)
[5]
Bromoacetic acid and dibromoacetic acid induce cardiotoxicity in larval zebrafish by triggering oxidative stress. — Mao X, Mo D, Lv M Comparative biochemistry and physiology. Toxicology & pharmacology : CBP (2026)
[6]
Toxicity profile of supratherapeutic loperamide: a systematic review and dose-response analysis. — Bekka E, Martinez-De la Torre A, Haschke M, Liakoni E, Weiler S Clinical toxicology (Philadelphia, Pa.) (2026)
[7]
Nicotinamide prevents anti-PD1 immune checkpoint inhibitor-associated early stages of cardiotoxicity. — Bai L, Zhao J, Dong K, Zhao M, Zhao Y, Cong Q et al. Science China. Life sciences (2026)
[8]
Cross-modal integration of metabolomics and cardiac functionality captures dynamic metabotoxic effects of doxorubicin in engineered heart tissues. — Conte F, Staykova DK, Cofiño-Fabres C, Snippert D, van Rooij A, Lefeber DJ et al. Stem cell reports (2026)
[9]
Sex Differences in Response to Acute Doxorubicin Cardiorespiratory Muscle Dysfunction and Preconditioning Exercise. — Montalvo RN, Nguyen BL, Doerr V, Dowllah IM, Wendler CC, Baumfalk DR et al. Medicine and science in sports and exercise (2026)
[10]
Calpain inhibition preserves myofilament integrity and prevents vandetanib-induced cardiac dysfunction. — Ji F, Huang J, Yan J, Lv S, Lu L, Wen H et al. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2026)
[11]
Emerging insights into traditional Chinese medicine interventions for chemotherapy-induced cardiotoxicity. — Li J, Zhang Z, Xu D, Fu R, Gong Z, Tang Y et al. Journal of ethnopharmacology (2026)
[12]
Prevention and Treatment of Doxorubicin and Trastuzumab-Induced Cardiotoxicity with Compound Danshen Dripping Pill. — Yu NX, Lin MM, Xu J, Cao B, Yang JH, Li RS et al. Chinese journal of integrative medicine (2026)
[13]
Novel Protective Role for Gut Microbiota-derived Metabolite PAGln in Doxorubicin-induced Cardiotoxicity. — Huang J, Hou X, Zhou N, Su N, Wei S, Yang Y et al. Cardiovascular drugs and therapy (2026)
[14]
Brexpiprazole induces acute cardiotoxicity via disrupting calcineurin/NFAT and calcium signaling pathway: A validation from biochemical, echocardiographic, histological, and computational analysis. — Alissa M, Alghamdi SA, Binshaya AS, Juraybi TN, Safhi AY, Albati AA et al. Tissue & cell (2026)
[15]
Cardiotoxicity Challenges in Nanomaterial: Risk Assessment, Mechanisms, and Mitigation Strategies. — Li Z, Liu L, Zhang P, Wen Z, Jia Y, Liao X International journal of nanomedicine (2026)
[16]
Progressive Conduction System Disease in Hydroxychloroquine Cardiotoxicity: A Call for Early Vigilance. — Vukićević M, Mehra MR, Padera RF, Isath A The American journal of cardiology (2026)
[17]
Crocin alleviates doxorubicin-mediated cardiotoxicity by activating PINK1-dependent cardiomyocyte mitophagy. — Su X, Fan T, Liu Z, Huang Y, Kan J, Liang C et al. Free radical biology & medicine (2026)
[18]
Advantages of long-term evaluation of doxorubicin-induced cardiotoxicity using human iPSC-derived cardiomyocyte sheet tissues with continuous contractile force measurement under constant pacing. — Hinata Y, Kagawa Y, Seno T, Kubo H, Kato E, Baba A et al. Toxicological sciences : an official journal of the Society of Toxicology (2026)
[19]
Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction. — Du W, Ringer M, Desai D, Khandakar GI, Tron Esqueda LE, Wang C et al. Circulation (2026)
[20]
Acute developmental toxicity and cardiotoxicity of Physalis alkekengi L. fruit and calyx extracts based on zebrafish (Danio rerio) model. — Zhou Z, Sun W, Yang L, Li Y, Guo H, Cui X et al. Journal of ethnopharmacology (2026)
[21]
Integrating qHTS and QSAR Models to Identify Safe GPCR-Targeted Compounds: A Focus on hERG-Dependent Cardiotoxicity. — Luo X, Zhao J, Sakamuru S, Xia M, Xu T, Travers J et al. Journal of chemical information and modeling (2026)
[22]
Isorhamnetin Protects Against Organophosphate-Induced Cardiac Damage in Wistar Rats Through Redox Balance and Nrf2/HO-1 Signalling. — Bseiso Y, Alotaibi BS, Aljabali AAA, Gammoh O, Oqal M, Rabeh ME et al. Basic & clinical pharmacology & toxicology (2026)
[23]
Isolating Ventricular Cardiomyocytes from a Mouse Model of Doxorubicin Cardiotoxicity. — Cheng Y, Jiang T, Xiao L, Wang N Journal of visualized experiments : JoVE (2026)
[24]
Acteoside targeting glutamine synthetase ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis. — Chu X, Zheng H, Sun J, Liu K, Shao Y, Han S et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[25]
Celastrol induces cardiotoxicity by directly targeting AMOTL2 and inhibiting YAP1/PGC-1α/TFAM-dependent mitochondrial biogenesis. — Shang H, Cheng H, Zhou W, Tang X, Han W, Zhang X et al. Chemico-biological interactions (2026)
[26]
Role of Sodium-Glucose Co-Transporter-2 Inhibitor During Anthracycline Use: An Updated Review. — Basham HA, Keswani S, Kumar A, Rahol Rai SKA, Surkasha F, Kumari A et al. Cardiology in review (2026)
[27]
Preventive Aerobic Training Protects Against Doxorubicin-Induced Cardiotoxicity by Preserving Redox Status and Attenuating Cardiac Stress-Related Signaling. — Ghignatti PVDC, Marschner RA, Ribeiro RT, Gayger-Dias V, Da Silva VF, Teixeira LV et al. Cells (2026)
[28]
From Oil Spills to Air Pollution: The Emergence of Phenanthrene as a Ubiquitous Cardiac Toxicant. — Shiels HA Annual review of physiology (2026)
[29]
Nepetin attenuates sertraline-induced cardiac dysfunction by modulating notch signaling, oxidative stress, and inflammation: Echocardiographic and histological evidence. — Otifi HM, Hayat MF, Bibi A, Hassan HM, Al-Emam A Tissue & cell (2026)
[30]
Targeting PFKFB3-dependent endothelial-mesenchymal transition by luteolin attenuates doxorubicin-induced cardiotoxicity. — Zhong X, Xia Y, Li N, Zhou M, Xie H, Shi T et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[31]
Montelukast attenuates diclofenac sodium-induced cardiotoxicity in male rats via targeting Wnt/β-catenin pathway. — Alsanea S, Albuhayri S, Alkharashi L, Ali N, AlAsmari AF, Arafah M et al. Scientific reports (2026)
[32]
Huanglian-ejiao decoction ameliorates doxorubicin-induced cardiomyocyte apoptosis and autophagic flux dysregulation by up-regulating ubiquilin1. — Zhang J, Li X, Sun L, Liu H, Jia T, Shen H et al. Journal of ethnopharmacology (2026)
[33]
Natural Compounds From Traditional Chinese Medicine Against Doxorubicin-Induced Cardiotoxicity: Biological Mechanisms and Therapeutic Potential. — Li M, Qiu R, Wang S, Xu Q, Li K, Chen H et al. Basic & clinical pharmacology & toxicology (2026)
[34]
Vitex Simplicifolia Abates Cadmium-Induced Cardiotoxicity Through Antioxidant Activity and Keap1 Targeting. — Chukwuma IF, Eze OI, Okeke OC, Apeh VO, Ezeorba TPC, Okafor C Chemistry & biodiversity (2026)
[35]
Nomilin mitigates OBS-induced developmental cardiotoxicity via the Nrf2 pathway. — Liu X, Fan Y, Chen R, Peng Y, Wu X, Xia M et al. Aquatic toxicology (Amsterdam, Netherlands) (2026)
[36]
Bergapten mitigates doxorubicin-induced cardiotoxicity via NOX4/Nrf2/HO-1 axis: Insights from in vitro and in vivo models. — Banik BK, Kundu S, Achary ST, Das B, Verma S, Mugale MN et al. Free radical biology & medicine (2026)
[37]
Integrative in silico-in vivo modeling identifies apigenin modulation of TGF-β1/SMAD2 in methotrexate-induced cardiotoxicity. — Zaitone SA, Lashine RM, Elabbasy LM, Elbassiouny MH, Hamad AG, Elzahed HM et al. Toxicology mechanisms and methods (2026)
[38]
Protective effects of propolis against metaflumizone induced cardiotoxicity through modulation of oxidative stress, inflammation, and the PI3K/Akt/mTOR pathway. — Başeğmez M, Dursun İ, Kara A, Gelen V, Çinar İ Archives of toxicology (2026)
[39]
Artesunate ameliorates doxorubicin-induced cardiotoxicity by promoting HuR binding to Sirt1 mRNA. — Wu S, Wang T, Mao Z, Yang Z, Wang Z, Jia Z et al. European journal of pharmacology (2026)
[40]
Ursolic acid ameliorates doxorubicin-induced cardiotoxicity by inhibiting DRP1-mediated excessive mitochondrial fission and oxidative stress. — Lin D, Dai X, Tang M, Wu Y, Xu H European journal of pharmacology (2026)
[41]
A simplified co-culture reveals altered cardiotoxic responses to doxorubicin in hPSC-derived cardiomyocytes in the presence of endothelial cells. — Brescia M, Gallant J, Chatrian A, Keselman P, Paulsson ES, Mol MPH et al. Stem cell reports (2026)
[42]
Short-term electrical stimulation promotes partial functional and morphological maturation of human-induced pluripotent stem cell-derived cardiomyocytes enabling cardiotoxicity risk mitigation at early-stage drug discovery for cardiac contractility modulation. — Miyoshi H, Morimura K, Hara R, Hori R, Watanabe E, Mochizuki N et al. Toxicological sciences : an official journal of the Society of Toxicology (2026)
[43]
A novel in vivo phenotypic assay to evaluate kinase inhibitor induced cardiotoxicity and strategies for cardioprotection. — Police SR, Borra V, Tatikonda S, Maddila KSM, Mediboina SG, Amanchi NR et al. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2026)
[44]
Cardiotoxicity associated with antifungal agents: A pharmacovigilance analysis of the FDA Adverse Event Reporting System. — Cao D, Wei C, Yuan Y, Wu B International journal of clinical pharmacology and therapeutics (2026)
[45]
Evaluation of Anthracycline-Induced Cardiotoxicity Using Proton Magnetic Resonance Spectroscopy Compared With Cardiac Functional Parameters　- An Animal Study. — Tu Y, Kou XY, Zhou J, Zhang XA, Li C, Zheng X et al. Circulation journal : official journal of the Japanese Circulation Society (2026)
[46]
CXCR2 promotes tacrolimus-related cardiotoxicity via activating the Src-mediated PI3K/Akt/mTOR pathway. — Chen X, Hu K, Zhang Y, Wang J, He SM, Yang Y et al. International immunopharmacology (2026)
[47]
Tongmai Yangxin Pill ameliorates doxorubicin-induced cardiotoxicity through m6A/ALKBH5/BNIP3 axis. — Zhao W, Wu Y, Li Y, Jiang Z, Li S, Liu J et al. Journal of ethnopharmacology (2026)
[48]
ROS-induced degradation of hERG potassium channels contributes to aripiprazole-induced prolongation of the QTc interval. — Cao YH, Wang XC, Wang HK, Yang ZK, Liu DD, Yang Y et al. Acta pharmacologica Sinica (2026)
[49]
Esculetin attenuates doxorubicin-induced cardiac toxicity: Evidence from gene expression, enzyme activity, and molecular docking analyses. — Demir Y, Ceylan H, Yeşilkent EN, Kizir D, Karaman M, Türkeş C et al. Computational biology and chemistry (2026)
[50]
Neutrophil-derived reactive oxygen species mediate doxorubicin-induced cardiotoxicity and skeletal myopathy. — Dzierlega K, Soliman AM, Chen H, Vu J, Parker D, Roberts B et al. American journal of physiology. Heart and circulatory physiology (2026)
[51]
Transgene-induced cardiotoxicity in high-dose AAV gene transfer. — Biquand A, Gicquel E, Poupiot J, Faivre M, Campuzano S, Bourgeton T et al. Molecular therapy : the journal of the American Society of Gene Therapy (2026)
[52]
PGAM1-dependent VDAC1 oligomerization disrupts mitochondrial quality control to drive doxorubicin cardiotoxicity via the cGAS-STING-ferroptosis axis. — Li Y, Zheng S, Zhuang H, Wu J, Wang J, Chang X Free radical biology & medicine (2026)
[53]
Esterase-Responsive Mitochondria-Targeted Hydropersulfide Donors Mitigate Doxorubicin Cardiotoxicity While Preserving Anticancer Activity. — Gu J, Liu Q, Rodriguez D, Lamar J, Bradley KR, Keceli G et al. Angewandte Chemie (International ed. in English) (2026)
[54]
New targets and biomarkers for doxorubicin-induced cardiotoxicity in humans: implications drawn from toxicogenomic data and molecular modelling. — Karakuş F, Ece A, Kuzu B Journal of biomolecular structure & dynamics (2026)
[55]
Herbacetin alleviates acute doxorubicin cardiotoxicity via regulating the ERK1/2-FOXO3a signaling pathway. — Bian S, Li X, Zhu P, Jiang Z, Yan C, Wei S et al. Human cell (2026)
[56]
Periplocin and bufalin induce cardiotoxicity by regulating AMPK/SIRT1/PGC-1α pathway to inhibit energy metabolism and trigger autophagy. — Gao X, Zhang J, Lin Y, Tian K, Tu J, Wu Z et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[57]
Serinc2-STAT3 protects against doxorubicin-induced cardiotoxicity via promoting mitochondrial bioenergetics. — Hu S, Yang M, Liu T, Huang M, Ju H, Liu Z et al. Redox biology (2026)
[58]
Doxorubicin-induced cardiotoxicity under 28 GHz 5G-band electromagnetic radiation in rats: Insights into the mitigative role of vitamin C. — Rahimi A, Rafati A, Mortazavi SMJ, Edalat F, Jooyan N, Naseh M et al. Toxicology and applied pharmacology (2026)
[59]
Forchlorfenuron exposure induces cardiotoxicity via NF-κB/NLRP3-mediated inflammasome activation independent of Septin2 inhibition. — Li Y, Meng Q, Liu J, Kang Z, Xu A, Xu Y et al. Free radical biology & medicine (2026)
[60]
Stereoselective disruption of copper homeostasis by prothioconazole induces cardiotoxicity via mitochondria-mediated apoptosis in zebrafish embryos. — Bian J, Zhao H, Xu W, Li Z, Zhang Y Pesticide biochemistry and physiology (2026)
[61]
Guizhi Gancao Decoction protects against doxorubicin-induced cardiotoxicity by intervening in microtubule acetylation. — Yao R, Huang J, Shan X, Li R, Chen H, Zhao P et al. Journal of ethnopharmacology (2026)
[62]
American ginseng-derived extracellular vesicle-like nanoparticles (AGELNs) mitigate doxorubicin-induced cardiotoxicity by inhibiting GPX4-mediated ferroptosis. — Liu T, Wang H, Wang R, Jin Y, Wang Y, Wang S et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2026)
[63]
Downregulated TRIM35 Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress and Inflammation via Inhibiting TLR4/NF-κB Pathway. — Hu Y, Wang S, Zhang C, He F, Jiang Y, Chen R et al. Cardiovascular drugs and therapy (2026)
[64]
Matrine triggers cardiotoxicity via apoptosis induced by reduction of GSH synthesis through the ATF4/CTH pathway. — Zheng X, Wu W, Li Y, Pan W, Xu Y, Zhong L et al. Toxicology and applied pharmacology (2026)
[65]
Elucidating the toxic mechanism of doxorubicin-induced cardiac ferroptosis through network toxicology and molecular docking. — Liu Y, He SH, Sun YX, Liu YW, Wang YT, Xiong J et al. Genomics (2026)
[66]
Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocytes pyroptosis mediated by the IL-6/STAT3-caspase-3/GSDME axis and M1 polarization of macrophages. — Huang X, Chen Y, Zhang Y, Hu X, Yang W, Pan T et al. Pharmacological research (2026)
[67]
Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity. — Díaz-Guerra A, Clemente-Moragón A, Pollán Á, López-Palomar L, Cádiz L, Ibáñez B Basic research in cardiology (2026)
[68]
Nickel-induced cardiotoxicity: immunopathogenesis, thromboinflammation, and a targeted nanotherapeutic strategy. — Joghataie P, Habibi Z, Bahrampour A, Danjeh M, Molaee P, Yousefi Chermehini N et al. International immunopharmacology (2026)
[69]
NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity. — Roberts JA, Batie M, Ponsford AH, Poh J, Hewitt BJ, Botfield HF et al. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026)
[70]
Chromatin remodeling factor CHRAC1 regulates doxorubicin-induced cardiotoxicity via IRF9/GSDMD/CASP-1. — Zang T, Zhou C, Yu Y, Lin W, Xu Q, Shen L Cellular signalling (2026)
[71]
Saxagliptin mitigates doxorubicin-induced cardiotoxicity by modulating NLRP3/caspase-1/IL-1β and TLR-4/NF-κB pathways. — Abdel-Fattah MM, Abozaid YM, Messiha BAS, Khalaf MM Toxicology and applied pharmacology (2026)
[72]
The role and mechanism of TXNDC5 in cardio-oncology: Killing two birds with one stone? — An N, Zhang X, Lin H, Xu Q, Dai Q, Kong Y et al. Current problems in cardiology (2025)
[73]
Systematic review and meta-analysis of right ventricular changes in cancer-therapy - The forgotten ventricle in cardio-oncology. — Fischer-Bacca CO, Huntermann R, de Oliveira JP, Alexandrino FB, Sato MY, Cardoso R et al. Current problems in cardiology (2025)
[74]
Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study. — Cai Y, Luo S, Lin S, Huang X, Wang X, Yang L et al. Scientific reports (2025)
[75]
Gender and age disparities in cardiac immune-related adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FAERS database. — Shan W, Zhu J, Shen J BMJ open (2025)
[76]
Practical application of multimodality imaging for cardio-oncology in Latin America. — Malhotra S, Peix A, Gutierrez-Villamil C, Bazan M, Giubbini R, Cueva C et al. Revista espanola de medicina nuclear e imagen molecular (2025)
[77]
Insights into mitochondrial creatine kinase: examining preventive role of creatine supplement in doxorubicin-induced cardiotoxicity. — Sharif SM, Hydock D Toxicology mechanisms and methods (2025)
[78]
Prx5 overexpression protect against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via the TLR4/NF-κB pathway. — Hu Y, Wang S, Zhang C, Shen C, Li Z, Jiang Y et al. International immunopharmacology (2025)
[79]
Urolithin A attenuates Doxorubicin-induced cardiotoxicity by enhancing PINK1-regulated mitophagy via Ambra1. — Wang X, Ma C, Mi K, Cao X, Tan Y, Yuan H et al. Chemico-biological interactions (2025)
[80]
Artemisia argyi mitigates doxorubicin-induced cardiotoxicity by inhibiting mitochondrial dysfunction through the IGF-IIR/Drp1/GATA4 signaling pathway. — Chen JK, Ramesh S, Islam MN, Shibu MA, Kuo CH, Hsieh DJ et al. Biotechnology and applied biochemistry (2025)
[81]
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. — Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres RA, Costa AN et al. Circulation (2025)
[82]
An Integrated Network Pharmacology and RNA-seq Approach for Exploring the Protective Effect of Andrographolide in Doxorubicin-Induced Cardiotoxicity. — Liu S, Liu J, Su N, Wei S, Xie N, Li X et al. Cardiovascular drugs and therapy (2025)
[83]
Diacylglycerol Kinase ζ Attenuates Doxorubicin-Induced Cardiotoxicity Through p53 Degradation. — Tachibana S, Otaki Y, Watanabe T, Goto J, Ochi H, Tanaka T et al. Journal of the American Heart Association (2025)
[84]
The FAK-NRF2 Axis Alleviates DOX-Induced Cardiotoxicity by Inhibiting Ferroptosis. — Zhao Y, Chen M, Kong L, Wu S, Teng C, Hu S et al. FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2025)
[85]
The Protective Effects of Carvacrol Against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo. — Retnosari R, Abdul Ghani MA, Majed Alkharji M, Wan Nawi WNIS, Ahmad Rushdan AS, Mahadi MK et al. Cardiovascular toxicology (2025)
[86]
Dibenzazepine, a γ-Secretase Enzyme Inhibitor, Protects Against Doxorubicin-Induced Cardiotoxicity by Suppressing NF-κB, iNOS, and Hes1/Hey1 Expression. — Badr AM, Alotaibi HN, El-Orabi N Inflammation (2025)
[87]
Taurine and enzymatically modified isoquercitrin synergistically protect against the methotrexate-induced cardiotoxicity in rats: antioxidant and antiapoptotic effects. — Mahmoud MM, Hegazy R, El-Sayed WM Drug and chemical toxicology (2025)
[88]
Esculin, a Coumarin Glucoside Prevents Fluoride-Induced Oxidative Stress and Cardiotoxicity in Zebrafish Larvae. — Babu S, Velmani NS, Manoharan S, Perumal E Environmental toxicology (2025)
[89]
Subchronic exposure to nonylphenol ethoxylate (NPE) induces cardiotoxicity and oxidative stress in American bullfrog tadpoles: a mechanistic approach. — Gonçalves YC, da Silva BH, de Godoy CR, Rantin FT, Kalinin AL, Monteiro DA Ecotoxicology (London, England) (2025)
[90]
Canagliflozin reverses doxorubicin-induced cardiotoxicity via restoration of autophagic homeostasis. — Luo J, He M, Liang C, Huang X, Zhu Y, Hu D et al. Toxicology and applied pharmacology (2025)
[91]
Chelerythrine triggers the prolongation of QT interval and induces cardiotoxicity by promoting the degradation of hERG channels. — Wang F, Wang B, Gu X, Li X, Liu X, Li B The Journal of biological chemistry (2025)
[92]
Cardiac Complications of Radiation Therapy. — Zaghlol R, Pedersen L, Qamer S, Yoo SGK, Ladin DA, Parvathaneni A et al. Cardiology clinics (2025)
[93]
The interplay between doxorubicin chemotherapy, antioxidant system, and cardiotoxicity: Unrevealing of the protective potential of tannic acid. — Kansu G, Ozturk N, Karagac MS, Yesilkent EN, Ceylan H Biotechnology and applied biochemistry (2025)
[94]
Protective effect of Lonicerae Japonicae Flos extract against doxorubicin-induced myocardial injury in mice and the possible mechanisms. — Xia S, Wei H, Hong W, Zhang Y, Yin F, Zhang Y et al. Nan fang yi ke da xue xue bao = Journal of Southern Medical University (2025)
[95]
Assessment of cardiotoxicity induced by PFOS exposure and mechanism research via untarget metabolomics. — Yang J, Guo M, Wu J, Li F, Xu S, Wang J et al. Drug and chemical toxicology (2025)
[96]
Human Cardiac Organoids: Advances and Prospects from Construction to Preclinical Drug Evaluation. — Chen M, Zhang T, Yang S, Niu Y, Ge Y, Chen Z et al. Cells (2025)
[97]
Deciphering the roles of cellular and extracellular non-coding RNAs in chemotherapy-induced cardiotoxicity. — Feng P, Yang F, Zang D, Bai D, Xu L, Fu Y et al. Molecular and cellular biochemistry (2025)
[98]
Metabolomics with gut microbiota analysis of podophyllotoxin-mediated cardiotoxicity in mice based on the toxicological evidence chain (TEC) concept. — Sun L, Liu J, Cheng Y, Wu Y, He T, Zhang Y et al. Chemico-biological interactions (2025)
[99]
Targeting the Gut-Heart Axis: Dextran from Gut-Derived — Hou J, Ren J, Abbas S, Song Y, Huang H, Cao M et al. Journal of agricultural and food chemistry (2025)
[100]
Ameliorative Effect of Empagliflozin and Linagliptin on Cisplatin-Induced Nephrotoxicity and Cardiotoxicity by Reducing Oxidative Stress. — Alharbi MS, Aldubayan MA Drug design, development and therapy (2025)

Share:Twitter Reddit LinkedIn